Roivant Sciences (ROIV) EBIT (2020 - 2025)
Roivant Sciences (ROIV) posted EBIT of -$930.3 million for Q4 2025, down 203.79% on a QoQ basis from -$306.2 million in Q3 2025, and down 29.51% year-over-year from -$1.3 billion in Q4 2024.
Roivant Sciences (ROIV) EBIT (2020 - 2025) Analysis & Trends
Roivant Sciences' EBIT history runs 6 years deep, the most recent figure standing at -$930.3 million for Q4 2025.
- Quarterly EBIT fell 29.51% year-over-year to -$930.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.2 billion (down 156.49% YoY) and the FY2026 annual result came in at -$515.1 million, up 48.66% from the prior year.
- EBIT was -$930.3 million for Q4 2025 at Roivant Sciences, down from -$306.2 million in the prior quarter.
- Across five years, EBIT topped out at $5.1 billion in Q4 2023 and bottomed at -$1.1 billion in Q4 2021.
- A 5-year average of -$98.3 million and a median of -$284.9 million in 2025 frame the typical range for EBIT.
- Annual changes were most pronounced in 2021 — EBIT tumbled 337.22% — and 2023, when it jumped 644.81%.
- Roivant Sciences' EBIT stood at -$1.1 billion in 2021, then rose by 13.25% to -$941.2 million in 2022, then soared by 644.81% to $5.1 billion in 2023, then sank by 114.01% to -$718.3 million in 2024, then decreased by 29.51% to -$930.3 million in 2025.
- Business Quant data shows ROIV's EBIT at -$930.3 million in Q4 2025, -$306.2 million in Q3 2025, and -$284.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -930.31 Mn |
| Sep 30, 2025 | -306.23 Mn |
| Jun 30, 2025 | -284.92 Mn |
| Dec 31, 2024 | -718.33 Mn |
| Sep 30, 2024 | -341.71 Mn |
| Jun 30, 2024 | -102.24 Mn |
| Dec 31, 2023 | 5.13 Bn |
| Sep 30, 2023 | -213.89 Mn |
| Jun 30, 2023 | -276.41 Mn |
| Dec 31, 2022 | -941.15 Mn |
| Sep 30, 2022 | -280.77 Mn |
| Jun 30, 2022 | -282.31 Mn |
| Dec 31, 2021 | -1.08 Bn |
| Sep 30, 2021 | -684.43 Mn |
| Jun 30, 2021 | -154.39 Mn |
| Dec 31, 2020 | -259.07 Mn |
| Sep 30, 2020 | -156.54 Mn |
| Jun 30, 2020 | -114.45 Mn |